In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors. Read More
Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment
Uncategorized |
26 Dec, 2025 |
Published
In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors. Read More
